WebAt Syros, we have identified cancer patients with aberrant expression of genes that can be targeted with new therapies. We are focused on applying this approach to developing new … WebSep 15, 2024 · CAMBRIDGE, Mass. & BEDMINSTER, N.J., September 15, 2024--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme ...
Syros Pharmaceuticals, Inc. (SYRS)
WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement SYRS July 5, 2024 Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 … WebJul 5, 2024 · Rare Daily Staff Syros Pharmaceuticals, a company focused on the development of medicines that control the expression of genes will acquire Tyme Technologies, a company developing cancer metabolism-based therapies with low toxicity profiles. Syros will acquire Tyme’s assets and net cash at closing, which after accounting … indy symbol
Syros and Tyme Technologies Announce Stockholder Approval of …
WebAug 9, 2024 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2024 and provided a corporate update. WebSYRS (Syros Pharmaceuticals) Other Long Term Assets as of today (April 14, 2024) is $8.43 Mil. Other Long Term Assets explanation, calculation, historical data WebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data login - memberdirect®